Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.
Harenberg
J
J
Vukojevic
Y
Y
Mikus
G
G
Joerg
I
I
Weiss
C
C
D006207:Half-Life; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D009844:Oligosaccharides / Q000493:pharmacokinetics*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence
D009844:Oligosaccharides; C479958:idraparinux